Loading...
XNAS
MBIO
Market cap5mUSD
Jul 09, Last price  
0.74USD
1D
8.84%
1Q
5.70%
IPO
-99.99%
Name

Mustang Bio Inc

Chart & Performance

D1W1MN
XNAS:MBIO chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
6.96%
Rev. gr., 5y
%
Revenues
0k
Net income
-2m
L-87.80%
-4,466,000-12,654,000-31,288,000-30,662,000-48,156,000-60,015,000-66,370,000-77,525,000-51,602,000-15,752,000-1,921,000
CFO
-5m
L-53.87%
-1,571,000-4,129,000-12,948,000-19,244,000-33,581,000-37,319,000-53,667,000-65,066,000-49,477,000-11,410,000-5,264,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
URL
https://www.mustangbio.com/
IPO date
Aug 22, 2017
Employees
113
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT